Skip to main content
Erschienen in: Annals of Surgical Oncology 10/2015

01.10.2015 | Breast Oncology

Normal Axillary Ultrasound Excludes Heavy Nodal Disease Burden in Patients with Breast Cancer

verfasst von: Rubie Sue Jackson, MD, MPH, Charles Mylander, PhD, Martin Rosman, MD, Reema Andrade, MBBS, Kristen Sawyer, MS, Thomas Sanders, PhD, Lorraine Tafra, MD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Axillary lymph node stage is important in guiding adjuvant treatment for breast cancer. The role of axillary ultrasound (AUS) in axillary staging is uncertain.

Methods

From an institutional database, all newly diagnosed invasive breast carcinomas from February 1, 2011 to October 31, 2014 were identified; exclusions were for stage IV disease, palpable adenopathy, or receipt of neoadjuvant chemotherapy. AUS findings, categorized as suspicious versus not suspicious, were correlated with the number of nodal metastasis from surgical pathology. The false-negative rate of nonsuspicious AUS for identifying ≥3 lymph nodes positive on final pathology was calculated.

Results

A total of 513 cancers were included. Overall, 400 AUSs were not suspicious (78 %), and 113 were suspicious (22 %). The sensitivity and specificity of AUS for predicting ≥3 nodal metastasis were 71 and 83 %, respectively. The false-negative rate for detecting ≥3 nodal metastasis was 4 %. False-negative rate was higher for lobular versus nonlobular carcinomas (12.0 vs. 2.3 %, p = 0.004) and for pT2–pT4 tumors versus pT1 tumors (8.2 vs. 1.7 %, p = 0.005).

Conclusions

Patients with normal axillary physical exam and ultrasound rarely harbor a large nodal disease burden. Randomized trials of sentinel lymph node biopsy versus no axillary surgery in patients with normal AUS must be powered for subgroup analysis of patients with invasive lobular carcinoma and pT2–pT4 tumors. Preoperative identification of nodal metastasis may decrease the need for second surgeries and identify candidates for neoadjuvant chemotherapy. AUS is a noninvasive means of predicting disease burden preoperatively and as such is a powerful tool to individualize treatment plans.
Literatur
1.
Zurück zum Zitat Foster Jr. RS (1996) The biologic and clinical significant of lymphatic metastases in breast cancer. Surg Oncol Clin N Am. 5(1):79–104.PubMed Foster Jr. RS (1996) The biologic and clinical significant of lymphatic metastases in breast cancer. Surg Oncol Clin N Am. 5(1):79–104.PubMed
2.
Zurück zum Zitat McGuire WL. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat. 1987;10(1):5–9.CrossRefPubMed McGuire WL. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat. 1987;10(1):5–9.CrossRefPubMed
3.
Zurück zum Zitat Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–53.CrossRefPubMed Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–53.CrossRefPubMed
4.
Zurück zum Zitat Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guidelines recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703–20.CrossRefPubMed Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guidelines recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703–20.CrossRefPubMed
5.
Zurück zum Zitat Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251(4):595–600.CrossRefPubMed Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251(4):595–600.CrossRefPubMed
6.
Zurück zum Zitat Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.CrossRefPubMed Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.CrossRefPubMed
7.
Zurück zum Zitat Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology in Milan (SOUND: sentinel node vs. observation after axillary ultrasound). Breast. 2012;21(5)678–81.CrossRefPubMed Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology in Milan (SOUND: sentinel node vs. observation after axillary ultrasound). Breast. 2012;21(5)678–81.CrossRefPubMed
8.
Zurück zum Zitat Cyr A, Gillanders W, Tucker N, et al. Axillary ultrasound with or without sentinel lymph node biopsy in detecting the spread of breast cancer in patients receiving breast conservation therapy. www.ClinicalTrials.gov identifier: NCT01821768. www.ClinicalTrials.gov. Accessed 14 March 2015. Cyr A, Gillanders W, Tucker N, et al. Axillary ultrasound with or without sentinel lymph node biopsy in detecting the spread of breast cancer in patients receiving breast conservation therapy. www.​ClinicalTrials.​gov identifier: NCT01821768. www.​ClinicalTrials.​gov. Accessed 14 March 2015.
9.
Zurück zum Zitat Fleiss JL. Statistical methods for rates and proportions, 2nd edn. New York: Wiley;1981. Fleiss JL. Statistical methods for rates and proportions, 2nd edn. New York: Wiley;1981.
10.
Zurück zum Zitat Cools-Lartigue J, Sinclair A, Trabulsi N, Meguerditchian A, Mesurolle B, Fuhrer R, Meterissian S. Preoperative axillary ultrasound and fine-needle aspiration biopsy in the diagnosis of axillary metastases in patients with breast cancer: predictors of accuracy and future implications. Ann Surg Oncol. 2013; 20(3):819–27.CrossRefPubMed Cools-Lartigue J, Sinclair A, Trabulsi N, Meguerditchian A, Mesurolle B, Fuhrer R, Meterissian S. Preoperative axillary ultrasound and fine-needle aspiration biopsy in the diagnosis of axillary metastases in patients with breast cancer: predictors of accuracy and future implications. Ann Surg Oncol. 2013; 20(3):819–27.CrossRefPubMed
11.
Zurück zum Zitat Schipper RJ, van Roozendaal LM, de Vries B, Pijnappel RM, Beets-Tan RG, Lobbes MB, Smidt ML. Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value? Breast. 2013;22(6):1108–13.CrossRefPubMed Schipper RJ, van Roozendaal LM, de Vries B, Pijnappel RM, Beets-Tan RG, Lobbes MB, Smidt ML. Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value? Breast. 2013;22(6):1108–13.CrossRefPubMed
12.
Zurück zum Zitat Abe H, Schacht D, Sennett CA, Newstead GM, Schmidt RA. Utility of preoperative ultrasound for predicting pN2 or higher stage axillary lymph node involvement in patients with newly diagnosed breast cancer. Am J Roentgenol. 2013;200(3):696–702.CrossRef Abe H, Schacht D, Sennett CA, Newstead GM, Schmidt RA. Utility of preoperative ultrasound for predicting pN2 or higher stage axillary lymph node involvement in patients with newly diagnosed breast cancer. Am J Roentgenol. 2013;200(3):696–702.CrossRef
13.
Zurück zum Zitat Choi JS, Kim MJ, Moon HJ, Kim EK, Yoon JH. False-negative results of preoperative axillary ultrasound in patients with invasive breast cancer: correlations with clinicopathologic findings. Ultrasound Med Biol. 2012;38(11):1881–6.CrossRefPubMed Choi JS, Kim MJ, Moon HJ, Kim EK, Yoon JH. False-negative results of preoperative axillary ultrasound in patients with invasive breast cancer: correlations with clinicopathologic findings. Ultrasound Med Biol. 2012;38(11):1881–6.CrossRefPubMed
14.
Zurück zum Zitat Johnson S, Brown S, Porter G, Steel J, Paisley K, Watkins R, Holgate C. Staging primary breast cancer. Are there tumour pathological features that correlate with a false-negative axillary ultrasound? Clin Radiol. 2011;66(6):497–9.CrossRefPubMed Johnson S, Brown S, Porter G, Steel J, Paisley K, Watkins R, Holgate C. Staging primary breast cancer. Are there tumour pathological features that correlate with a false-negative axillary ultrasound? Clin Radiol. 2011;66(6):497–9.CrossRefPubMed
15.
Zurück zum Zitat Meretoja TJ, Heikkila PS, Mansfield AS, et al. A predictive tool to estimate the risk of axillary metastases in breast cancer patients with negative axillary ultrasound. Ann Surg Oncol. 2014;21(7):2229–36.CrossRefPubMed Meretoja TJ, Heikkila PS, Mansfield AS, et al. A predictive tool to estimate the risk of axillary metastases in breast cancer patients with negative axillary ultrasound. Ann Surg Oncol. 2014;21(7):2229–36.CrossRefPubMed
16.
Zurück zum Zitat Stachs A, Göde K, Hartmann S, et al. Accuracy of axillary ultrasound in preoperative nodal staging of breast cancer: size of metastases as a limiting factor. SpringerPlus. 2013;2:350.PubMedCentralCrossRefPubMed Stachs A, Göde K, Hartmann S, et al. Accuracy of axillary ultrasound in preoperative nodal staging of breast cancer: size of metastases as a limiting factor. SpringerPlus. 2013;2:350.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Boughey JC, Ballman KV, Hunt KK, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015; 33: Epub ahead of print. Boughey JC, Ballman KV, Hunt KK, et al. Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American College of Surgeons Oncology Group Z1071 Trial (Alliance). J Clin Oncol. 2015; 33: Epub ahead of print.
18.
Zurück zum Zitat Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) Clinical Trial. JAMA. 2013; 310(14):1455–61.PubMedCentralCrossRefPubMed Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) Clinical Trial. JAMA. 2013; 310(14):1455–61.PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2014; 33(3):258–64.CrossRefPubMed Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2014; 33(3):258–64.CrossRefPubMed
21.
Zurück zum Zitat Kuehn T, Bauerfeind I, Fleige B, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicenter cohort study. Lancet Oncol. 2013;14(7):609–18.CrossRefPubMed Kuehn T, Bauerfeind I, Fleige B, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicenter cohort study. Lancet Oncol. 2013;14(7):609–18.CrossRefPubMed
Metadaten
Titel
Normal Axillary Ultrasound Excludes Heavy Nodal Disease Burden in Patients with Breast Cancer
verfasst von
Rubie Sue Jackson, MD, MPH
Charles Mylander, PhD
Martin Rosman, MD
Reema Andrade, MBBS
Kristen Sawyer, MS
Thomas Sanders, PhD
Lorraine Tafra, MD, FACS
Publikationsdatum
01.10.2015
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2015
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4717-7

Weitere Artikel der Ausgabe 10/2015

Annals of Surgical Oncology 10/2015 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.